|1.||Ding, Jian: 3 articles (11/2010 - 01/2005)|
|2.||Lu, Da-Yong: 2 articles (11/2010 - 07/2006)|
|3.||Huang, Min: 2 articles (07/2006 - 01/2005)|
|4.||Ohshima, Koichi: 1 article (07/2014)|
|5.||Toyoda, Kosuke: 1 article (07/2014)|
|6.||Abe, Yasunobu: 1 article (07/2014)|
|7.||Tsuda, Mariko: 1 article (07/2014)|
|8.||Choi, Ilseung: 1 article (07/2014)|
|9.||Uike, Naokuni: 1 article (07/2014)|
|10.||Suehiro, Youko: 1 article (07/2014)|
|1.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
04/01/1993 - "MST-16 was shown to be effective in ATLL, which has no standard therapy. "
01/01/1992 - "Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16."
04/01/1993 - "Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). "
01/01/1992 - "Orally administered MST-16 is a promising agent for the treatment of ATLL."
01/01/1992 - "Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). "
11/01/1991 - "Late phase II trial of MST-16 for malignant lymphoma was conducted by the multi-institutions collaboration. "
11/01/1991 - "This study indicated that MST-16 was a useful agent against malignant lymphoma including primary resistant or relapsed patients, and that the recommended regimen for a late phase II study was considered to be 1,600-2,400 mg/body/day for 5-7 days repeatedly with a pause of several days. "
06/01/1994 - "The clinical phase studies proved that sobuzoxane was quite effective for the treatment of malignant lymphoma (overall response rate in phase II study 29.7%) and adult T cell leukemia (response rate for acute type: 46.2%). "
03/01/1992 - "A late phase II study with MST-16 for malignant lymphoma was performed with the collaboration of 11 institutions belonging to the Hanshin Hematological Disease Treatment Research Group. "
02/01/1999 - "Sobuzoxane, a topoisomerase II inhibitor, is useful for the treatment of lymphoma, especially adult T cell leukemia/lymphoma. "
09/01/1991 - "[A case of RAEB-t treated by G-CSF showing complete remission after MST-16 treatment for subsequent reversible leukemia]."
01/01/2005 - "Our data show that Pro may be more effective against lung cancer and leukemia while ICRF-187 and MST-16 shows similar IC50 values only against leukemia. "
01/01/1991 - "Therapeutic efficacy of MST-16 was heavily dependent on the treatment schedule: 9 daily oral administrations and treatment every 4 h on day 1 only were much more effective against s.c.-implanted L1210 leukemia than a single dose or five daily administrations giving the same total dose. "
03/01/1994 - "In vivo experiments, the combination of MST-16 and MGBCP markedly prolonged the survival time of mice bearing P388 or L1210 leukemia. "
03/18/1992 - "Future trials of combination chemotherapy using MST-16 with other antitumor drugs are warranted in view of the additive effects observed in studies of MOLT-3 cells and studies of L1210 leukemia in mice."
07/09/1992 - "The effects of MST-16, a new antitumor agent derived from bis (2, 6-dioxopiperazine), on cell growth, cell-cycle progression and DNA synthesis, alone and in combination with other antitumor agents, were investigated in murine leukemia L1210 cells in vitro. "
01/01/1990 - "Further studies revealed that MST-16 has considerable therapeutic activity against a number of other tumors such as ascitic forms of L1210 leukemia, colon 26 adenocarcinoma, and MH-134 hepatoma and solid forms of B16 melanoma, Lewis lung carcinoma, colon 38 adenocarcinoma, and M5076 fibrosarcoma. "
01/01/2005 - "It suggests that Pro has a wider spectrum of cytotoxic effects against human tumor cells than other bisdioxopiperazines, especially against solid tumors, and with a single cytotoxic pathway of Pro and MST-16 affecting chromosome segregation and leading also to cell G2/ M phase arrests, which finally reduces cell division rates. "
01/01/2005 - "Cytotoxic activities and mechanisms of Raz (+)-steroisomer (ICRF-187, dexrazoxane), Pro and MST-16 against tumor cells were evaluated by MTT colorimetry, flow cytometry and karyotyping. "
01/01/1998 - "Similarly, tumor growth in mice treated with THP (10 mg/kg) or ME (10 mg/kg) with MST-16 (750 mg/kg) was significantly delayed. "
01/01/1998 - "In colon 26 tumor-bearing mice, a significant delay in tumor growth was noted in the mice treated with ADM (7.5 mg/kg) and MST-16 (750 mg/kg) compared with mice given either drug alone. "
01/01/1991 - "Furthermore, MST-16 significantly inhibited growth of human colon, lung and breast cancers implanted s.c. "
|2.||Etoposide (VP 16)
|3.||Type II DNA Topoisomerases (Topoisomerase II)
|5.||Topoisomerase II Inhibitors
|6.||Granulocyte Colony-Stimulating Factor (G-CSF)
|8.||Antineoplastic Agents (Antineoplastics)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Renal Dialysis (Hemodialysis)
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Drug Therapy (Chemotherapy)